Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
crispr
7
×
deals
7
×
life sciences
national blog main
san francisco blog main
7
×
biotech
boston top stories
national top stories
san francisco top stories
startups
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
indiana blog main
indiana top stories
national
new york blog main
new york top stories
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
abbvie
biogen
cancer immunotherapy
clinical trials
editas medicine
gene editing
ipo
allergan
What
bio
roundup
gene
medicines
crispr
develop
editing
life
millions
new
science
talk
years
abbvie
acquisitions
alliance
announced
approval
available
bails
based
becker
big
billions
biogen’s
biopharmaceutical
biosciences
biotech
brand
bridgebio
capital
car
cas
ceo
cheaper
collabs
companies
convo
covid
create
Language
unset
Current search:
crispr
×
deals
×
" san francisco blog main "
×
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Bio Roundup: Michael Becker, Suzanne Eaton, Gene Therapy Moves & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M